The Changes in Carotid Plaque Neovascularization After Elovocumab Therapy
The Changes in Carotid Plaque Neovascularization After Elovocumab Therapy
150 selected patients will be recruited, who have at least one atherosclerotic plaque in the
 carotid artery that is thicker than 2.0 mm and which is determined to be uniformly or
 predominantly echolucent by standard ultrasonography. For each of the plaques, standard
 ultrasonography will be used to evaluate lesion echogenicity, while contrast-enhanced
 ultrasonography (CEUS) will be used to perform the visual and quantitative analysis of
 neovascularization. Each technique will be applied at baseline (at the time of study
 enrollment) and following 0.5、1 year of Elococumab Injection treatment. During the study,
 these patients will be treated with Elococumab Injection (1ml:140mg),ih, every two weeks.
Inclusion Criteria:

 -  1. have at least one atherosclerotic plaque in the carotid artery that is thicker than
 2.0 mm and which is determined to be uniformly or predominantly echolucent by standard
 ultrasonography;

 -  2.patients were referred for optimal medical treatment;

 -  3.patients agreed to undergo follow-up CEUS at half-year and 1-year interval.

 Exclusion Criteria:

 -  1.patients had previous history of cerebral thrombosis or cerebral embolism;

 -  2.patients were contraindicated to the usage of contrast media;

 -  3.image quality of baseline or follow-up CEUS was severely impaired (in presence of
 severe artifact, non-diagnostic);

 -  4.patients withdrew the informed consents during follow-up;

 -  5.patients experienced major adverse cerebrovascular events during follow-up;

 -  6.patients refused to undergo follow-up CEUS;

 -  7.lost follow-up